Sulfaphenazole derivatives as tools for comparing cytochrome P4502C5 and human cytochromes P4502Cs: Identification of a new high affinity substrate common to those enzymes

被引:21
作者
Marques-Soares, C
Dijols, S
Macherey, AC
Wester, MR
Johnson, EF
Dansette, PM
Mansuy, D
机构
[1] Univ Paris 05, Chim & Biochim Pharmacol & Toxicol Lab, UMR 8601 CNRS, F-75270 Paris 06, France
[2] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA USA
关键词
D O I
10.1021/bi027391+
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The inhibitory effects of a series of sulfaphenazole (SPA) derivatives were studied on two modified forms of rabbit liver cytochrome P450 2C5 (CYP2C5), CYP2C5dH, and structurally characterized CYP2C5/3LVdH and compared to the previously described effects of these compounds on human CYP2C8, 2C9, 2C18, and 2C19. SPA and other negatively charged compounds that potently inhibit CYP2C9 had very little effect on CYP2C5dH, whereas neutral, N-alkylated derivatives exhibited IC50 values between 8 and 22 muM. One of the studied compounds, 4, that derives from SPA by replacement of its NH2 substituent with a methyl group and by N-methylation of its sulfonamide moiety, acted as a good substrate for all CYP2Cs used in this study. Hydroxylation of the benzylic methyl of 4 is the major reaction catalyzed by all of these CYP2C proteins, whereas hydroxylation of the N-phenyl group of 4 was observed as a minor reaction. CYP2C5dH, 2C5/3LVdH, 2C9, 2C18, and 2C19 are efficient catalysts for the benzylic hydroxylation of 4, with K-m values between 5 and 13 muM and k(cat) values between 16 and 90 min(-1). The regioselectivity observed for oxidation of 4 by CYP2C5/3LVdH was easily interpreted on the basis of the existence of two different binding modes of 4 characterized in the experimentally determined structure of the complexes of CYP2C5/3LVdH with 4 described in the following paper [Wester, M. R. et al. (2003) Biocheinistii; 42, 6370-6379].
引用
收藏
页码:6363 / 6369
页数:7
相关论文
共 28 条
[1]   Competitive CYP2C9 inhibitors:: Enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis [J].
Afzelius, L ;
Zamora, I ;
Ridderström, M ;
Andersson, TB ;
Karlén, A ;
Masimirembwa, CM .
MOLECULAR PHARMACOLOGY, 2001, 59 (04) :909-919
[2]   CHIMERAS OF THE HUMAN CYTOCHROME-P450 1A FAMILY PRODUCED IN YEAST - ACCUMULATION IN MICROSOMAL-MEMBRANES, ENZYME-KINETICS AND STABILITY [J].
BELLAMINE, A ;
GAUTIER, JC ;
URBAN, P ;
POMPON, D .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 225 (03) :1005-1013
[3]  
CORNISHBOWDEN A, 1995, FUNDAMENTALS ENZYMES
[4]   Engineering microsomal cytochrome P4502C5 to be a soluble, monomeric enzyme - Mutations that alter aggregation, phospholipid dependence of catalysis, and membrane binding [J].
Cosme, J ;
Johnson, EF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (04) :2545-2553
[5]   Development of a combined protein and pharmacophore model for cytochrome P4502C9 [J].
de Groot, MJ ;
Alex, AA ;
Jones, BC .
JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (10) :1983-1993
[6]  
DeVleeschauwer M, 1997, SYNLETT, P375
[7]   BIOCHEMISTRY AND MOLECULAR-BIOLOGY OF THE HUMAN CYP2C SUBFAMILY [J].
GOLDSTEIN, JA ;
DEMORAIS, SMF .
PHARMACOGENETICS, 1994, 4 (06) :285-299
[8]  
Guengerich FP, 1995, CYTOCHROME P, P473
[9]   Synthesis of sulfaphenazole derivatives and their use as inhibitors and tools for comparing the active sites of human liver cytochromes P450 of the 2C subfamily [J].
Ha-Duong, NT ;
Dijols, S ;
Marques-Soares, C ;
Minoletti, C ;
Dansette, PM ;
Mansuy, D .
JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (22) :3622-3631
[10]   Interaction of new sulfaphenazole derivatives with human liver cytochrome P4502Cs: Structural determinants required for selective recognition by CYP2C9 and for inhibition of human CYP2Cs [J].
Ha-Duong, NT ;
Marques-Soares, C ;
Dijols, S ;
Sari, MA ;
Dansette, PM ;
Mansuy, D .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2001, 394 (02) :189-200